drugset / Trial / NCT05376904

A Trial of HR18034 for Postoperative Analgesia in Subjects Undergoing Hemorrhoidectomy.

NCT05376904

Phase 2 Completed 86 enrolled Shanghai Hengrui Pharmaceutical Co., Ltd.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The study is being conducted to evaluate the efficacy, and safety of HR18034 for postoperative analgesia in subjects undergoing hemorrhoidectomy. To explore the reasonable dosage of HR18034 for postoperative analgesia in subjects undergoing hemorrhoidectomy.

Timeline

Start
2022-06-13
Primary completion
2022-10-05
Completion
2022-10-05

Drugs

EvaluationDrugModalityDoseRoute
Subject HR18034 Unknown
Comparator Ropivacaine Other / unclassified

Indications

No indication recorded.